Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
Open Access
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (4) , 718-722
Abstract
Objective To assess the long-term efficacy and safety of infliximab plus methotrexate in juvenile rheumatoid arthritis (JRA). Methods Patients eligible for the open-label extension (OLE, weeks 52–204) received infliximab 3–6 mg/kg every 8 weeks plus methotrexate. Results Of the 78/122 (64%) children entering the OLE, 42 discontinued infliximab, most commonly due to consent withdrawal (11 patients), lack of efficacy (eight patients) or patient/physician/sponsor requirement (eight patients). Infliximab (mean dose 4.4 mg/kg per infusion) was generally well tolerated. Infusion reactions occurred in 32% (25/78) of patients, with a higher incidence in patients positive for antibodies to infliximab (58%, 15/26). At week 204, the proportions of patients achieving ACR-Pedi-30/50/70/90 response criteria and inactive disease status were 44%, 40%, 33%, 24% and 13%, respectively. Conclusions In the limited population of JRA patients remaining in the study at 4 years, infliximab was safe and effective but associated with a high patient discontinuation rate. Clinical trials registration number NCT00036374.Keywords
This publication has 15 references indexed in Scilit:
- Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2008
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialThe Lancet, 2008
- A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2007
- Juvenile idiopathic arthritisThe Lancet, 2007
- Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.2004
- Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexateAnnals of the Rheumatic Diseases, 1998
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997
- Measurement of health status in children with juvenile rheumatoid arthritisArthritis & Rheumatism, 1994
- Methotrexate in Resistant Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 1992
- A study of classification criteria for a diagnosis of juvenile rheumatoid arthritisArthritis & Rheumatism, 1986